Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

metabolic profiles

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (1) Amine N-methyltransferase (1) Amylin Receptor (2) Apoptosis (3) Bacterial (1) Biochemical Assay Reagents (2) Caspase (1) DNA/RNA Synthesis (1) Drug Metabolite (1) Endogenous Metabolite (5) Fluorescent Dye (1) GCGR (2) Gli (1) GLP Receptor (1) Hedgehog (1) HIV (2) Influenza Virus (1) Insulin Receptor (2) LPL Receptor (1) Monoamine Oxidase (1) Paraptosis (1) Phosphatase (1) PI4K (1) Potassium Channel (1) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Reverse Transcriptase (1) ROR (1) SARS-CoV (1) Serotonin Transporter (1) Sigma Receptor (2) Smo (1) Trace Amine-associated Receptor (TAAR) (1) Virus Protease (1)
By Research Areas:	Cancer (8) Endocrinology (1) Infection (5) Inflammation/Immunology (5) Metabolic Disease (6) Neurological Disease (5)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156654

Ibuzatrelvir 1 Publications Verification PF-07817883	SARS-CoV Virus Protease	Infection
Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M ^pro and 3CL ^pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .

HY-B2209

Hydroxocobalamin 3 Publications Verification Vitamin B12a	Endogenous Metabolite	Neurological Disease Metabolic Disease
Hydroxocobalamin (Vitamin B12a) is a cyanide antidote. Hydroxocobalamin can decrease the cell and plasma cyanide concentrations and increase survival rate in acute cyanide poisoning. Hydroxocobalamin can improve newborn Cbl-C defect-induced metabolic profile and neurocognitive outcome. Hydroxocobalamin can normalize Vitamin B₁₂ deficiency. Hydroxocobalamin can induce acute kidney injury. Hydroxocobalamin can be used for the researches of metabolic and neurological disease .

HY-P11274A

Zenagamtide sodium Amycretin sodium; NN 9487 sodium	Amylin Receptor Insulin Receptor GCGR	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-138657

NCGC00378430 2 Publications Verification	Phosphatase	Cancer
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model .

HY-P11274

Zenagamtide Amycretin; NN 9487	Amylin Receptor GCGR Insulin Receptor	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-112613

UCB9608 1 Publications Verification	PI4K	Inflammation/Immunology
UCB9608 is a potent, selective and orally active PI4KIIIβ inhibitor, with an IC₅₀ of 11 nM, selective over PI3KC2 α, β, and γ lipid kinases. UCB9608 improves metabolic stability and exhibits excellent pharmacokinetic profile, acts as a potent immunosuppressive agent .

HY-W011215

Dihexyl phthalate 1 Publications Verification	Apoptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology
Dihexyl phthalate is one of the commonly used phthalate esters in various plastics and consumer products. Dihexyl phthalate is classified as a priority pollutant and an endocrine disruptor. Dihexyl phthalate can induce reactive oxygen species (ROS) accumulation, promote inflammation, and lead to significant increases in apoptosis and inflammation-related gene expression levels. Dihexyl phthalate can cause testicular atrophy and is a reproductive toxicant .

HY-15286

Sodium 4-pentynoate	Biochemical Assay Reagents	Others
Sodium 4-pentynoate is a alkynylacetate analogue, can be metabolically incorporated onto cellular proteins through biosynthetic mechanisms for profiling of acetylated proteins in diverse cell types . Sodium 4-pentynoate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147319

RTI-7470-44	Trace Amine-associated Receptor (TAAR)	Neurological Disease
RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC₅₀ value of 8.4 nM and a K_i value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .

HY-161316

NNMT-IN-5	Amine N-methyltransferase	Neurological Disease Metabolic Disease Cancer
NNMT-IN-5 (Compound 3-12) is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC₅₀ = 47.9 ± 0.6 nM). NNMT-IN-5 also has an excellent selectivity profile over a panel of human methyltransferases. NNMT-IN-5 can be used for the research of cancer, diabetes, metabolic disorders, and neurodegenerative diseases .

HY-N7921

Urolithin M6	Bacterial	Others
Urolithin M6 is a polyhydroxy-rich metabolite with potential antioxidant activity. Urolithin M6 is produced by intestinal microbial metabolism and may act as an analog of tannic acid compounds. The production of Urolithin M6 in humans requires specific bacterial 3-dehydroxylase activity, which provides a new mechanism for its biotransformation. The metabolic profile of Urolithin M6 helps to stratify volunteers and further explore its potential role in health and disease .

HY-W052051

N-Benzylacetamide N-Acetylbenzylamine	Endogenous Metabolite	Others
N-Benzylacetamide (N-Acetylbenzylamine), as an endogenous metabolite, is the major component of the plasma metabolic profile of Benznidazole (HY-B1548) .

HY-178767

ECC-5004	GLP Receptor	Metabolic Disease
ECC-5004 (Compound 1) is a GLP-1 receptor agonist with an EC₅₀ of 0-20 nM. ECC-5004 exhibits strong inhibitory effects on OATP1B1, with an IC₅₀ < 1 μM. ECC-5004 can be used to study diseases such as diabetes, obesity, and non-alcoholic fatty liver disease .

HY-178341

NNRT-IN-13	Reverse Transcriptase HIV	Infection
NNRT-IN-13 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor that directly inhibiting HIV-1 reverse transcriptase (IC₅₀ = 0.25 μM). NNRT-IN-13 exhibits excellent antiviral activity against wild-type HIV-1 (EC₅₀ = 0.0046 μM) and a broad spectrum of drug-resistant mutants. NNRT-IN-13 exhibits favorable in vivo metabolic and safety profiles. NNRT-IN-13 can be used for human immunodeficiency virus (HIV) research .

HY-175984

S1P1 agonist 7	LPL Receptor	Inflammation/Immunology
S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC₅₀_{(G‑protein)} = 12.7 nM and EC₅₀_{(β‑arrestin)} = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research .

HY-13550A

Ametantrone acetate NSC 196473 acetate; NSC 290813 acetate	DNA/RNA Synthesis	Cancer
Ametantrone acetate (NSC 196473 acetate) is an antineoplastic drug with topoisomerase II inhibitory activity. Ametantrone acetate causes covalent cross-linking of DNA. The pharmacokinetic profile of Ametantrone acetate has been confirmed in clinical trials, and its elimination pathway in the body indicates the existence of a major metabolic pathway .

HY-126321

RORγt agonist 1	ROR	Cancer
RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC₅₀ of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy .

HY-W800840

Alkyne sphinganine	Biochemical Assay Reagents	Others
Alkyne Sphinganine a metabolic labeling reagent that contains a terminal alkyne moiety that allows for the subsequent tagging of protein?lipid complexes by click chemistry. The terminal alkyne group can be used in a highly specific linking reaction with azide-containing reagents, known as ‘click chemistry’, in the presence of a copper (Cu)-containing catalyst allowing for the visualization and proteomic profiling of protein?sphingolipid complexes in living cells.

HY-131914B

EST64454 maleate	Sigma Receptor	Inflammation/Immunology
EST64454 maleate is a highly soluble σ1 receptor antagonist, demonstrating potent antinociceptive properties for pain treatment. EST64454 maleate exhibits excellent metabolic stability across various species and possesses an adequate pharmacokinetic profile in rodents. EST64454 maleate has been identified as a promising clinical candidate due to its favorable aqueous solubility and high permeability in Caco-2 cells.

HY-122229

GS-9822	HIV	Infection
GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC₅₀ of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys .

HY-155992

WLB-89462	Sigma Receptor	Neurological Disease
WLB-89462 (Compound 20c) is a selective σ2 receptor ligand (K_i: 13 nM). WLB-89462 has neuroprotective activity. WLB-89462 improves short-term memory impairment induced by Aβ peptide in rats. WLB-89462 has good ADMET profile (good solubility, no CYP inhibition, good metabolic stability, high permeability, brain penetration, and high oral exposure in rodents) .

HY-16469

SR 13668	Akt	Cancer
SR13668 is a potent indole analog derived from indole-3-carbinol (I3C), known for its natural anticancer properties but limited by poor metabolic characteristics. Developed to enhance I3C's anticancer efficacy, SR13668 effectively inhibits growth factor-stimulated Akt activation. It demonstrates strong oral anticancer activity across different cancer types in preclinical studies, showing promise in clinical development due to its favorable safety profile and potent therapeutic effects .

HY-W052051R

N-Benzylacetamide (Standard) N-Acetylbenzylamine (Standard)	Endogenous Metabolite Reference Standards	Others
N-Benzylacetamide (Standard) is the analytical standard of N-Benzylacetamide (HY-W052051). This product is intended for research and analytical applications. N-Benzylacetamide (N-Acetylbenzylamine), as an endogenous metabolite, is the major component of the plasma metabolic profile of Benznidazole (HY-B1548) .

HY-W011215R

Dihexyl phthalate (Standard)	Apoptosis Reactive Oxygen Species (ROS) Reference Standards	Inflammation/Immunology
Dihexyl phthalate (Standard) is the analytical standard of Dihexyl phthalate (HY-W011215). This product is intended for research and analytical applications. Dihexyl phthalate is one of the commonly used phthalate esters in various plastics and consumer products. Dihexyl phthalate is classified as a priority pollutant and an endocrine disruptor. Dihexyl phthalate can induce reactive oxygen species (ROS) accumulation, promote inflammation, and lead to significant increases in apoptosis and inflammation-related gene expression levels. Dihexyl phthalate can cause testicular atrophy and is a reproductive toxicant .

HY-143330

MAO-B-IN-4	Monoamine Oxidase	Neurological Disease
MAO-B-IN-4 (Compound 26) is an orally active and reversible MAO-B inhibitor with an IC₅₀ of 9 nM. MAO-B-IN-4 has good metabolic stability, safety profile and brain permeability. MAO-B-IN-4 shows antidepressant activity in rats and mice. MAO-B-IN-4 can be used in studies related to Alzheimer's disease .

HY-D3198

NIR‐fluorescent ceramide	Fluorescent Dye Endogenous Metabolite	Cancer
NIR-fluorescent ceramide is a neutral near-infrared (NIF) fluorescent probe (λ_em=650 nm) based on the C-bridged nitrobenzoxadiazole SCOTfluor core, which enables visualization of lipid metabolic processes such as sphingolipid trafficking. The emission signal of NIR-fluorescent ceramide increases significantly in liposomal environments. NIR-fluorescent ceramide acts as an intracellular trafficking tracer, localizing to regions surrounding the endoplasmic reticulum and Golgi apparatus within a short period, and then translocating to recycling lysosomes over a longer period, thus enabling real-time visualization of sphingolipid trafficking and biological lipid functions in living cells. NIR-fluorescent ceramide also generates metabolic uptake profiles and provides multiple metabolic readouts in human cancer cell lines .

HY-139792

Besigliptin tosylate SHR117887	Endogenous Metabolite	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-180919

ERG-IN-5	Potassium Channel Drug Metabolite	Cancer
ERG-IN-5 (Compound M1) is a metabolite of ERG-IN-4 (HY-180918), and it is a hERG potassium channel inhibitor with an IC₅₀ of 1.5 μM. ERG-IN-5 is cytotoxic to MTAP ^del HCT116 and its CC₅₀ is 28 nM. ERG-IN-5 can be used for the study of colon cancer .

HY-182244

SERT/NET-IN-1	Serotonin Transporter 5-HT Receptor	Endocrinology
SERT/NET-IN-1 is a blood-brain barrier-permeable SERT and NET inhibitor, with an IC₅₀ of 11.2 nM against human SERT and an IC₅₀ of 32.0 nM against human NET. SERT/NET-IN-1 blocks 5-HT reuptake to enhance serotonergic signaling. SERT/NET-IN-1 also blocks norepinephrine reuptake to enhance central noradrenergic transmission and inhibits the ejaculatory reflex. SERT/NET-IN-1 prolongs ejaculatory latency, reduces ejaculation frequency and preserves sexual function. SERT/NET-IN-1 exhibits cross-species microsomal metabolic stability, shows acceptable oral brain exposure in rats, and has favorable safety profiles. SERT/NET-IN-1 can be used in studies related to premature ejaculation .

HY-180452

HAT-IN-10	Paraptosis	Infection
HAT-IN-10 (Compound 12a) is an anti-human African trypanosomiasis (HAT) agent, with an EC₅₀ value of 0.23 μM for T. brucei. HAT-IN-10 can be used for research on HAT .

HY-183335

SMO-IN-6	Smo Hedgehog Gli Apoptosis Caspase	Cancer
Anticancer agent 321 is a Smoothened (SMO) inhibitor with a human IC₅₀ of 0.12 μM, enhanced aqueous solubility, good plasma and metabolic stability, moderate therapeutic index, preliminary safety profile, and moderate oral bioavailability in rats.Anticancer agent 321 binds to SMO’s 7-transmembrane helical channel, forming hydrogen bonds with Asp384 and hydrophobic/π-π interactions with His470, Phe391, Tyr394, stabilizing SMO’s inactive conformation to inhibit Hedgehog/GLI signaling.Anticancer agent 321 inhibits proliferation, suppresses colony formation, induces apoptosis, and downregulates Hedgehog/GLI pathway target genes GLI1, GLI2, Ptch1, HHip in cancer cells.Anticancer agent 321 inhibits tumor growth, downregulates Ki67 and SOX2, and upregulates cleaved-caspase 3 in tumor tissues.Anticancer agent 321 can be used for the research of cutaneous squamous cell carcinoma .

HY-180525

PB2-IN-2	Influenza Virus	Infection
PB2-IN-2 is an orally active PB2 inhibitor with RNA-dependent RNA Polymerase (RNP) IC₅₀ = 0.2 nM, LRA (Ligand Receptor Assay) EC₅₀ = 0.8 nM, Cytopathic Effect (CPE) EC₅₀ = 0.1 nM. PB2-IN-2 exhibits broad-spectrum, nanomolar antiviral potency against a panel of influenza A strains (including H1N1pdm09, Lyon/1337/2007/H1N1, Tex12-Like/H3N2, PR/8/34/H1N1, WSN/1933/H1N1, rPR8(H1N1)/H7N9 with EC₅₀ = 1.5, 3.6, 3.7, 13.8, 2.9 and 9.8 nM and all the CC₅₀ values > 2 μM. PB2-IN-2 possesses an excellent pharmacokinetic profile and metabolic stability. PB2-IN-2 can be used for anti-influenza research .

Cat. No.	Product Name

HY-L105S

Peptide Compound Library	826 compounds
Peptides, composed of amino acids, serve as crucial building blocks for proteins and have gained significant attention in drug development over the past decade. The advancements in production, modification, and analytical technologies have led to a surge in the potential applications of peptides in medicine. Peptides offer a number of advantages over small molecule drugs, including: greater target specificity and efficacy, more predictable metabolic profiles, easier delivery to where they are needed in the body, and fewer side effects. Peptides are increasingly appearing in all branches of medicine as components of innovative drugs, imaging agents, diagnostic agents, and other complex drugs such as peptide-drug conjugates. To date, more than 80 peptide drugs have been approved to treat a variety of diseases, including microbial infections, obesity, anti-diabetes, and cancer, as well as to develop cell targeting platforms and improve cell penetration properties. MCE designs a unique collection of 826 peptide compounds. HY-L105S is a peptide compound library that can be provided with solution form based on HY-L105, and can be applied to peptides-based drug development.

Peptide Compound Library

826 compounds

Peptides, composed of amino acids, serve as crucial building blocks for proteins and have gained significant attention in drug development over the past decade. The advancements in production, modification, and analytical technologies have led to a surge in the potential applications of peptides in medicine. Peptides offer a number of advantages over small molecule drugs, including: greater target specificity and efficacy, more predictable metabolic profiles, easier delivery to where they are needed in the body, and fewer side effects. Peptides are increasingly appearing in all branches of medicine as components of innovative drugs, imaging agents, diagnostic agents, and other complex drugs such as peptide-drug conjugates. To date, more than 80 peptide drugs have been approved to treat a variety of diseases, including microbial infections, obesity, anti-diabetes, and cancer, as well as to develop cell targeting platforms and improve cell penetration properties.

MCE designs a unique collection of 826 peptide compounds. HY-L105S is a peptide compound library that can be provided with solution form based on HY-L105, and can be applied to peptides-based drug development.

Cat. No.	Product Name	Type

HY-D3198

NIR‐fluorescent ceramide	Fluorescent Dyes
NIR-fluorescent ceramide is a neutral near-infrared (NIF) fluorescent probe (λ_em=650 nm) based on the C-bridged nitrobenzoxadiazole SCOTfluor core, which enables visualization of lipid metabolic processes such as sphingolipid trafficking. The emission signal of NIR-fluorescent ceramide increases significantly in liposomal environments. NIR-fluorescent ceramide acts as an intracellular trafficking tracer, localizing to regions surrounding the endoplasmic reticulum and Golgi apparatus within a short period, and then translocating to recycling lysosomes over a longer period, thus enabling real-time visualization of sphingolipid trafficking and biological lipid functions in living cells. NIR-fluorescent ceramide also generates metabolic uptake profiles and provides multiple metabolic readouts in human cancer cell lines .

NIR‐fluorescent ceramide

Fluorescent Dyes

NIR-fluorescent ceramide is a neutral near-infrared (NIF) fluorescent probe (λ_em=650 nm) based on the C-bridged nitrobenzoxadiazole SCOTfluor core, which enables visualization of lipid metabolic processes such as sphingolipid trafficking. The emission signal of NIR-fluorescent ceramide increases significantly in liposomal environments. NIR-fluorescent ceramide acts as an intracellular trafficking tracer, localizing to regions surrounding the endoplasmic reticulum and Golgi apparatus within a short period, and then translocating to recycling lysosomes over a longer period, thus enabling real-time visualization of sphingolipid trafficking and biological lipid functions in living cells. NIR-fluorescent ceramide also generates metabolic uptake profiles and provides multiple metabolic readouts in human cancer cell lines .

Cat. No.	Product Name	Target	Research Area

HY-P11274A

Zenagamtide sodium Amycretin sodium; NN 9487 sodium	Amylin Receptor Insulin Receptor GCGR	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-P11274

Zenagamtide Amycretin; NN 9487	Amylin Receptor GCGR Insulin Receptor	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

Hydroxocobalamin 3 Publications Verification Vitamin B12a	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Hydroxocobalamin (Vitamin B12a) is a cyanide antidote. Hydroxocobalamin can decrease the cell and plasma cyanide concentrations and increase survival rate in acute cyanide poisoning. Hydroxocobalamin can improve newborn Cbl-C defect-induced metabolic profile and neurocognitive outcome. Hydroxocobalamin can normalize Vitamin B₁₂ deficiency. Hydroxocobalamin can induce acute kidney injury. Hydroxocobalamin can be used for the researches of metabolic and neurological disease .

Dihexyl phthalate 1 Publications Verification	Natural Products Pyrus bretschneideri Rehder Rosaceae Plants Source Classification	Apoptosis Reactive Oxygen Species (ROS)
Dihexyl phthalate is one of the commonly used phthalate esters in various plastics and consumer products. Dihexyl phthalate is classified as a priority pollutant and an endocrine disruptor. Dihexyl phthalate can induce reactive oxygen species (ROS) accumulation, promote inflammation, and lead to significant increases in apoptosis and inflammation-related gene expression levels. Dihexyl phthalate can cause testicular atrophy and is a reproductive toxicant .

Urolithin M6	Monophenols Phenols Endogenous metabolite Source Classification	Bacterial
Urolithin M6 is a polyhydroxy-rich metabolite with potential antioxidant activity. Urolithin M6 is produced by intestinal microbial metabolism and may act as an analog of tannic acid compounds. The production of Urolithin M6 in humans requires specific bacterial 3-dehydroxylase activity, which provides a new mechanism for its biotransformation. The metabolic profile of Urolithin M6 helps to stratify volunteers and further explore its potential role in health and disease .

N-Benzylacetamide N-Acetylbenzylamine	Natural Products Endogenous metabolite Source Classification	Endogenous Metabolite
N-Benzylacetamide (N-Acetylbenzylamine), as an endogenous metabolite, is the major component of the plasma metabolic profile of Benznidazole (HY-B1548) .

N-Benzylacetamide (Standard) N-Acetylbenzylamine (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
N-Benzylacetamide (Standard) is the analytical standard of N-Benzylacetamide (HY-W052051). This product is intended for research and analytical applications. N-Benzylacetamide (N-Acetylbenzylamine), as an endogenous metabolite, is the major component of the plasma metabolic profile of Benznidazole (HY-B1548) .

Dihexyl phthalate (Standard)	Structural Classification Natural Products Pyrus bretschneideri Rehder Rosaceae Plants Source Classification	Apoptosis Reactive Oxygen Species (ROS) Reference Standards
Dihexyl phthalate (Standard) is the analytical standard of Dihexyl phthalate (HY-W011215). This product is intended for research and analytical applications. Dihexyl phthalate is one of the commonly used phthalate esters in various plastics and consumer products. Dihexyl phthalate is classified as a priority pollutant and an endocrine disruptor. Dihexyl phthalate can induce reactive oxygen species (ROS) accumulation, promote inflammation, and lead to significant increases in apoptosis and inflammation-related gene expression levels. Dihexyl phthalate can cause testicular atrophy and is a reproductive toxicant .

Cat. No.	Product Name		Classification

HY-15286

Sodium 4-pentynoate		Alkynes
Sodium 4-pentynoate is a alkynylacetate analogue, can be metabolically incorporated onto cellular proteins through biosynthetic mechanisms for profiling of acetylated proteins in diverse cell types . Sodium 4-pentynoate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

metabolic profiles

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

NaturalProducts

Click Chemistry

Natural
Products